within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB17_CerliponaseAlfa;

model CerliponaseAlfa
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 7.666666666666665e-08,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.21,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CerliponaseAlfa</td></tr><tr><td>ATC code:</td><td>A16AB17</td></tr><td>route:</td><td>intraventricular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>210</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.6</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) used as an enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease, also known as Batten disease). It is approved for intraventricular administration in pediatric patients with CLN2 disease to slow the loss of ambulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric CLN2 patients (mean age 5 years) receiving recommended dosage.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A16AB17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CerliponaseAlfa;
